Line Schmidt Tarpgaard

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance

Niels F. Jensen, Jan Stenvang, Mette K. Beck et al. · Molecular Oncology · 2015 · 139 citations · Full text

Medicine, Cancer Biology, Oncology +16

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells

Mads H. Rasmussen, Iben Lyskjær, Rosa Jersie-Christensen et al. · Nature Communications · 2016 · 96 citations · Full text

Medicine, Molecular Biology, Oncology +17

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

Mogens K. Boisen, Julia S. Johansen, Christian Dehlendorff et al. · Annals of Oncology · 2013 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

High expression of microRNA‐625‐3p is associated with poor response to first‐line oxaliplatin based treatment of metastatic colorectal cancer

Mads H. Rasmussen, Niels F. Jensen, Line Schmidt Tarpgaard et al. · Molecular Oncology · 2013 · 86 citations · Full text

Medicine, Molecular Biology, Oncology +15